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Abstract
Lysosomal sequestration of anti-cancer compounds reduces drug availability at intracellular target sites, thereby
limiting drug-sensitivity and inducing chemoresistance. For hepatocellular carcinoma (HCC), sorafenib (SF) is the ﬁrst
line systemic treatment, as well as a simultaneous activator of autophagy-induced drug resistance. The purpose of this
study is to elucidate how combination therapy with the FDA-approved photosensitizer verteporﬁn (VP) can potentiate
the antitumor effect of SF, overcoming its acquired resistance mechanisms. HCC cell lines and patient-derived in vitro
and in vivo preclinical models were used to identify the molecular mechanism of action of VP alone and in
combination with SF. We demonstrate that SF is lysosomotropic and increases the total number of lysosomes in HCC
cells and patient-derived xenograft model. Contrary to the effect on lysosomal stability by SF, VP is not only
sequestered in lysosomes, but induces lysosomal pH alkalinization, lysosomal membrane permeabilization (LMP) and
tumor-selective proteotoxicity. In combination, VP-induced LMP potentiates the antitumor effect of SF, further
decreasing tumor proliferation and progression in HCC cell lines and patient-derived samples in vitro and in vivo. Our
data suggest that combination of lysosome-targeting compounds, such as VP, in combination with already approved
chemotherapeutic agents could open a new avenue to overcome chemo-insensitivity caused by passive lysosomal
sequestration of anti-cancer drugs in the context of HCC.
Introduction
Autophagy and lysosomes play an important role in all
eukaryotic cells, by restoring homeostasis after intra- or
extracellular stress conditions1,2. They are both part of the
intracellular catabolic machinery, often driving che-
motherapy resistance, as well as tumor proliferation1,3,4.
Nadanaciva et al. showed that several compounds and
anticancer drugs, including tyrosine kinase inhibitors
(TKIs), such as sunitinib, have a high afﬁnity for the lyso-
somal compartment due to their chemical structure5. The
process by which chemotherapeutic agents undergo intra-
cellular compartmentalization within the lumen of lyso-
somes is called lysosomotropism and it can reduce their
potency at the speciﬁc target sites6–8. The acidic environ-
ment of the lysosomes, together with the fact that che-
motherapeutics are often formulated as weak-bases, enables
their accumulation within their lumen by simple diffusion.
Immediately after their internalization, lysosomotropic
compounds become protonated, resulting in their lysoso-
mal compartmentalization9–12. Various strategies are being
sought to overcome lysosome-mediated chemoresistance,
such as lysosomal photodestruction, targeting lysosomal
acid sphingomyelinase (ASM) and inducing lysosomal
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membrane permeabilization (LMP)9,13–16. In hepatocellular
carcinoma (HCC), a notoriously difﬁcult to treat tumor17
and second leading cause of cancer-related deaths world-
wide18, autophagy and lysosomes seem to play a pivotal role
in chemotherapy resistance against the oral FDA-approved
ﬁrst line TKI sorafenib (SF)19,20. Indeed, SF was shown to
induce autophagy as an adaptive response mechanism as
well as to be less effective on HCC cells with larger or
increased numbers of lysosomes at basal level19,20. Due to
tumor cell adaptive responses, development of SF-induced
resistance is one of the major causes of treatment failure in
patients with advanced HCC6,17. Verteporﬁn (VP), is a
benzoporphyrin derivate belonging to the porphyrin family
and already used as a photosensitizer for photodynamic
therapy in macular degeneration21. For cancer therapy, VP
was initially used as a photosensitizer, able to eliminate
tumor cells by the production of oxygen radicals by non-
thermal light activation21,22. VP has also been investigated
in the absence of light, showing anti-tumor properties due
to the inhibition of autophagosome formation as well as
tumor-speciﬁc proteotoxicity, independently of its descri-
bed target Yes-associated protein 1 (YAP1)23–26. Here we
report how VP-induced lysosomal membrane permeabili-
zation can circumvent intracellular catabolic factors limiting
the efﬁcacy of SF. Our ﬁndings reveal that by speciﬁcally
targeting the tumor lysosomal compartment stability and
autophagic ﬂux progression, VP can unravel a new strategy
to overcome the chemo-insensitivity of SF in the context
of HCC.
Materials and methods
Cell lines and primary human hepatocyte cultures
All HCC cell lines were purchased from American Type
Culture Collection (ATCC - LCG Promochem) and cul-
tured either in Dulbecco’s Modiﬁed Eagle’s or RPMI
medium 1640 (Life Technology) with 10% of FBS,
100 U/mL Penicillin and 100 μg/mL Streptomycin (Life
Technology). Human immortalized microvascular endo-
thelial cells (HMEC-1) were purchased from ATCC and
cultured in MCDB 131 medium with 5% of FBS, 10 ng/mL
of HEGF (Sigma-Aldrich), 1 ng/mL of hydrocortisone
(Sigma-Aldrich) and antibiotics. Murine ﬁbroblast
NIH3T3 MET M1268T cell lines stably and ectopically
expressing K-RAS (G12D, G12V, G13D) and H-RAS
(G12V) mutations were kindly provided by Prof. Yitzhak
Zimmer (Department for BioMedical Research (DBMR),
University of Bern, Switzerland) and maintained in DMEM
(Gibco) supplemented with 10% FBS and antibiotic-
antimycotic 0.5mg/ml Geneticin/G-418 sulfate (Gibco)27.
Normal liver tissue was obtained from surgical resections
from consented patients at the University Hospital of Bern.
Hepatocytes were isolated by enzymatic perfusion, as
previously described28. All cultured cells were kept at
37 °C in a humidiﬁed incubator with 5% of CO2.
Chemicals and reagents
Stock solutions of verteporﬁn (VP - SML0534 - Sigma-
Aldrich) were dissolved in dimethyl sulfoxide (DMSO –
10mmol/L) at the time of use. Resazurin sodium salt
(R7017 - Sigma-Aldrich) was prepared in sterile distilled
water (15 mmol/L) to be used as an indicator of cell via-
bility in mammalian cell cultures. BAY 54-9085 (sorafenib
tosylate - SF) was obtained from Bayer HealthCare
Pharmaceuticals, chloroquine (CQ - C6628), baﬁlomycin
A1 (BafA - B1793) and Leu-Leu methyl ester hydro-
bromide (LLOMe – L7393) were all purchased from
Sigma-Aldrich.
Cell proliferation and cytotoxicity assays
Cells (2,5 × 103 per well) were seeded in 96-well ﬂat
bottom plates. All the cells were treated as indicated,
taking as a control cells treated with the appropriate
vehicle. For Resazurin cell viability assay, the viability of
treated cells was measured by adding 10% of the media
volume of the Resazurin stock solution for 2 h. Lumi-
nescence was measured with Tecan Inﬁnite® 200 Plate
Reader at wavelengths 545 nm and 590 nm. The coefﬁ-
cient of drug interaction (CDI) was calculated as pre-
viously described29. Cytotoxicity was assessed using an
LDH cytotoxicity detection kit (Roche) according to the
manufacturer’s guidelines. All the experiments were
performed in darkness and treated cells were protected
from light using aluminum foil in order to avoid VP
photo-activation. All experiments were performed in
triplicates.
RNA extraction and quantitative real-time RT-PCR (qPCR)
RNA was isolated from cells as well as tissue samples
by TRIzol Reagent following the manufacture’s protocol
(Life Tecnologies). cDNA was synthesized using
Omniscript RT Kit 200 (Qiagen). mRNA was analyzed
by reverse transcriptase-quantitative PCR (RT-qPCR;
ABI 7900, SDS 2.4 software). Expression levels of human
genes of interest were measured by TaqMan mastermix
(Roche). All the primers used were from Thermo Fisher
Scientiﬁc.
Cell-cycle analysis by Flow cytometry
Cells ﬁxed with 70% EtOH were incubated for 2 h with
RNase A (40 μg – Promega)/Propidium iodide solution
(50 μg–Sigma-Aldrich). Cell-cycle distribution was
determined by ﬂuorescence-activated cell sorting FACS
using the LSR II and FACSDiva software (Becton Dick-
inson). All experiments were performed with three sam-
ples per condition.
Angiogenesis tube formation assay in 3D Matrigel®
HMEC-1 cells were seeded at a density of 1.5 × 104 cells
per well in a 96-well plate, previously coated with 30 μL of
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Matrigel® (DB Biosciences). Pictures were taken with a
Leica camera and afterwards analyzed by a semi-
automated plug-in for ImageJ software as previously
described by Gilles Carpentier (2012). All experiments
were performed in triplicate.
Live-cells ﬂuorescence microscopy and Lysotracker
ﬂuorescence assay
For live-cell imaging, HCC cell lines and primary human
hepatocytes were seeded (1.5 × 104 cells per well) in a
chambered coverglass (Thermo Scientiﬁc) and treated as
indicated before. After 24 h cells were washed twice in cold
DPBS and stained with LysoTracker DNS-99 (Thermo
Fisher). Nuclei were counterstained with DAPI (1:5000).
Verteporﬁn auto-ﬂuorescence was observed in the far-red
spectrum (Cy5 channel). Fluorescence images of live-cells
were obtained using an automated inverted microscope
(Leica DMSI4000 B). For the Lysotracker ﬂuorescence
assay, HCC cells were seeded (1.5 × 104 cells per well) on a
96-well assay plate and treated as described. After 24 h,
medium was aspirated and discarded from all the wells
followed by Lysotracker incubation as previously repor-
ted30. LysoTracker ﬂuorescence intensity was then mea-
sured by spectrophotometry (Ex= 577 nm, Em= 590 nm)
on a ﬂuorescence plate reader (Tecan Inﬁnite® 200).
Calcium phosphate transfection and GFP-WIPI-1 puncta
analysis
For transient calcium phosphate transfection, HuH7
and HepG2 cells were seeded on coverslips and grown to
70–80% conﬂuence in culture medium at 37 °C and 5%
CO2. Cells were transfected as previously shown
31 with
GFP-WIPI-1 plasmid DNA (kindly provided by Prof.
Tassula Proikas-Cezanne, University of Tübingen).
Approximately 24 h later, transfected cells were treated as
described, washed with PBS and ﬁxed in 4% for-
maldehyde. Nuclei were counterstained with DAPI
(1:5000) and analyzed by confocal microscopy (Olympus
FV1000, Olympus, Volketswil, Switzerland) at 60x mag-
niﬁcation. The number of GFP-WIPI-1 dots was quanti-
ﬁed using ImageJ software and using a modiﬁed version of
the plugin described elsewhere32.
Immunocytochemistry
HCC cell lines were grown on glass cover slips in 24-
well plates (2 × 104 cells per well) and treated as indicated
before. Cells were ﬁxed with 4% formaldehyde, permea-
bilized and blocked in 5% goat serum (DAKO, X0907),
0.3% Triton-X-100 (Sigma-Aldrich) in DPBS and stained
with anti-galectin-1 antibody (Abcam – 1:1000) and
matched with Alexa Fluor® (AF) 488 conjugated sec-
ondary antibodies (Life Technologies -1:1000). Nuclei
were counterstained with DAPI (1:5000), coverslips were
mounted with VECTASHIELD Antifade Mounting
Medium (Vector Laboratories, H-1000) and ﬂuorescence
images were taken using an automated inverted micro-
scope (Leica DMSI4000 B).
Western blot analysis
All total protein lysates were obtained using RIPA
buffer 10 mM Tris, pH8, 1 mM EDTA, pH8, 150mM
NaCl; phosphatase inhibitors (Na3VO4, NaF, PMSF); a
protease inhibitor mix (Sigma-Aldrich) and 0.5% NP40.
Western blots were performed according to standard
protocols. Primary antibodies were purchased as follows:
polyclonal anti-LC3B (Novus Biologicals - 1:1000), poly-
clonal anti-p62/SQSTM1 (Sigma-Aldrich - 1:1000),
polyclonal anti-PARP (Cell Signaling – 1:1000), polyclonal
anti-caspase 3 (Cell Signaling – 1:1000), monoclonal anti-
LAMP-1 (Santa Cruz Biotechnology – 1:1000), mono-
clonal anti-Hsp70 (Abcam – 1:2000), polyclonal anti-
pERK1/2 (Cell Signaling – 1:1000), polyclonal anti-ERK1/
2 (Abcam – 1:1000), polyclonal anti-pan RAS (Cell Sig-
naling –1:1000), phosphor-mTOR (Ser 2448; Cell Sig-
naling – 1:1000), mTOR (Cell Signaling – 1:1000);
phosphor-S6 kinase (Cell Signaling – 1:1000); S6 kinase
(Cell Signaling – 1:1000), phosphor-4E-BP1 (Cell Signal-
ing – 1:1000), 4E-BP1 (Cell Signaling – 1:1000) and
monoclonal anti-β-actin-peroxidase clone AC-15 (Sigma
Aldrich - 1:100000). HRP-conjugated secondary anti-
bodies were purchased as follows: goat anti-rabbit (1:1000
- Dako), goat anti-mouse (1:1000 - Dako). Membranes
were incubated with enhanced chemiluminescence
(Western Lightning Plus-ECL - Perkin Elmer) and ﬁlms
were developed by CURIX 60 (AGFA) or Fusion-FX7
SPECTRA (VILBER). The band size was estimated using
Precision Plus ProteinTM Dual Color Standards (BIO-
RAD).
Lysosomal pH measurements by ﬂow cytometry
Lysosomal pH measurements were based on a detailed
protocol recently published by Eriksson et al.33. In brief,
HCC cell lines and primary human hepatocytes were
seeded and cultured in cell culture medium containing
FITC-Dextran (0.1 mg/mL - FD40S - Sigma-Aldrich) for
three days. After this period FITC-Dextran was removed
by aspirating the medium and fresh cell culture medium
was added with the respective treatments as indicated.
Lysosomal pH from samples belonging to the standard
curve scale (pH ranging from 4 to 6) and experimental-
treated ones were analyzed by FACS. Triplicate samples
were taken for each condition analyzed.
HCC patient-derived tumoroid cultures
HCC surgical resections were obtained from consented
patients at University Hospital of Bern. Enzymatic diges-
tion of minced tissue and 3D tumoroids culture were
performed as previously described34. For the drug-
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sensitivity assay, tumoroids were plated in Costar® Ultra-
Low Attachment 96-well plate (Corning) with expansion
medium supplemented with VP, SF and the respective
vehicles. Tumoroid-viability assay was conducted as pre-
viously described34. Brieﬂy, HCC patient-derived tumor-
oids (PDT) viability was assessed by CellTiter-Glo® 3D
Cell Viability Assay (Promega) after 2 days of drugs
incubation, according to the manufacturer’s guidelines.
To assess the tumoroid 3D structure and morphology,
bright-ﬁeld images were taken using an automated
inverted microscope (Leica DMSI4000 B).
Subcutaneous HCC cell line and patient-derived xenograft
mouse models
Eight- to twelve-week-old male Rag2−/−γc
−/− mice
were used for the subcutaneous xenograft model. In total
2 × 106 HepG2 cells were injected in a 1:1 ratio with
Matrigel® (BD Biosciences). HCC patient-derived speci-
mens were transplanted subcutaneously. Tumor volume
was measured using a digital caliper thanks to a modiﬁed
ellipsoid formula: volume= (4/3) × π × (length/2) ×
(width/2) × (height/2). Upon reaching a volume of
250mm3, animals were randomly divided into different
groups as described: verteporﬁn (100 mg/kg) was admi-
nistered every second day by intraperitoneal injection;
sorafenib (60 mg/kg) daily by oral gavage; combined
treatment with VP and SF; administration of the respec-
tive vehicles only (control group). The tumor volume and
the body weight were recorded every second day for
fourteen days. At the end of experiment, the entire tumor
was carefully removed and some snap-frozen samples
were stored in liquid nitrogen and kept at −80 °C until
further use. Other parts of the tissue were ﬁxed in 4%
formaldehyde and in Tissue-Tek Optimal Cutting Tem-
perature Compound from Sakura-Finetek® (O.C.T.TM) for
histological analysis. All animal experiments were con-
ducted in accordance to Swiss Guidelines of Care and Use
of Laboratory Animals.
Immunohistochemistry and immunoﬂuorescence
Tissue samples were ﬁxed in 4% formaldehyde, pro-
cessed, embedded in parafﬁn and sectioned with Leica
Microtome. Sections were stained using Ki67 antibody
(Abcam) and CD31 antibody (Abcam). For each sample
three randomly chosen ﬁelds were imaged by Leica
camera and analyzed by ImageJ software. Cryo-sections
(5 μm thick) were incubated with LAMP-1 primary
antibody (Santa Cruz Biotechnology) followed by the
Anti-Mouse IgG1 FITC (eBioscience) secondary antibody.
Verteporﬁn auto-ﬂuorescence was observed in the far-red
spectrum. Coverslips were mounted with VECTASHIELD
Antifade Mounting Medium with DAPI (Vector Labora-
tories, H-1500) and ﬂuorescence images were taken using
an automated inverted microscope (Leica DMSI4000 B).
Statistical analysis
Values are presented as means ± SEM. Statistical dif-
ferences for single comparisons were determined using
unpaired, two-tailed Student t tests, as well as 1-way or 2-
way analysis of variance (ANOVA). Tukey’s post-test was
performed to examine differences between drug treat-
ment effects. Longitudinal growth in vivo data were used
to test the difference of the tumor growth among treat-
ment groups. P values < 0.05 were considered statistically
signiﬁcant. Statistical analyses were carried out using
GraphPad Prism 7.
Results
Verteporﬁn decreases hepatocellular carcinoma cell
viability and potentiates the antitumor effect of sorafenib
Here, we tested the effect of VP in HCC, in the absence
of its light activation and demonstrated that in HepG2
and HuH7 cells there was a loss of cell viability in a dose-
and time-dependent manner (Fig. 1a and Supplementary
Fig. S1A), which was accompanied with increased cell
cytotoxicity (Fig. 1b). The cytotoxic effect of VP was more
pronounced in HuH7 cells and coincided with an increase
in cells in the sub-G1 phase and a decrease in the G1
phase compared to HepG2 (Supplementary Fig. S1B-C).
We next determined if VP is able to potentiate sorafenib
(SF), the ﬁrst-line FDA-approved oral multi-kinase inhi-
bitor used for advanced HCC. SF used as a single agent
did not impair tumor cell viability, while in combination
with VP there was a synergistic effect in HuH7 cells
(coefﬁcient of drug interaction (CDI)= 0.62) and an
additive effect in HepG2 (CDI= 0.97). This was accom-
panied by an increase of cell cytotoxicity (Fig. 1c, d). We
next analyzed the effect of SF, VP and their combination
on HCC patient-derived HCC tumoroids (PDTs) in vitro.
As observed in the HCC cell lines, SF had no effect on
PDT survival, however, PDTs exposed to VP displayed a
loss of three-dimensional structure (Fig. 1e), and a loss of
viability (Fig. 1f). Using an in vivo patient-derived xeno-
graft (PDX) model, we demonstrated that SF in combi-
nation with VP markedly reduced tumor growth and
progression compared to vehicle and SF alone (Fig. 1g).
The antitumor effect of SF and VP was characterized by a
signiﬁcant decrease of proliferating, Ki67-positive cells as
well as a signiﬁcant downregulation of expression of cell-
cycle progression genes, cyclin-A2 (CCNA2) and cyclin-
B1 (CCNB1; Fig. 1h, i). The anti-angiogenic capability of
SF was observed by CD31 staining, in which VP and SF-
treated tumors had signiﬁcantly less intra-tumor vascu-
lature, as well as by downregulation of vascular endo-
thelial growth factor A (VEGF-A) gene expression
(Fig. 1h, i). Knowing the effect of VP on the transcrip-
tional complex Yes-associated protein 1 (YAP1) of the
Hippo signaling pathway25, we conﬁrmed the signiﬁcant
downregulation of YAP1 target genes such as connective
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Fig. 1 (See legend on next page.)
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tissue growth factor (CTGF) and cysteine-rich angiogenic
inducer 61 (CYR61) in vitro for both HCC cell lines,
without any regulation when combined with SF (Supple-
mentary Fig. 1D). Interestingly, the apoptotic marker
caspase 3 was already less expressed at its pro-caspase
levels for both HCC cell lines and for all the VP- and SF/
VP-treated animals (Supplementary Fig. S1E-F). Increased
levels of cleaved poly ADP ribose polymerase (PARP)
were only observed on the most sensitive cell line HuH7
and in SF/VP-treated mice (Supplementary Fig. S1E-F).
The inhibitory effect of VP on HCC growth in vivo was
conﬁrmed using HepG2 cells in a subcutaneous HCC
xenograft mouse model (Supplementary Fig. S2A-C). The
effect of SF and VP on angiogenesis was tested using
human immortalized microvascular endothelial cells
(HMEC-1) in an in vitro tube formation assay (Supple-
mentary Fig. S2D). Interestingly, VP-treated HMEC-
1 cells also showed a decrease of newly formed vascu-
lature, however there was no synergistic or additive effect
in combination with SF (Supplementary Fig. S2E). These
results suggest that VP has a negative effect on the pro-
liferation and progression of HCC and augments the
effect of SF in vitro and in vivo.
VP induces lysosomal membrane permeabilization due to
the alkalinization of lysosomal pH
VP is a chlorinated benzoporphyrin derivative mono-
acid ring which contains a photoactive ring that is auto
ﬂuorescent in the far-red spectrum (660–780 nm)21.
Interestingly, we found a cytoplasmic co-localization of
VP with LysoTracker-stained lysosomes, which then led
to an increase of their number and an alteration of their
shape in both HCC cell lines (Fig. 2a, b and Supplemen-
tary Fig. S3A). VP induced the alkalinization of the lyso-
somal lumen pH in a dose-dependent manner, similar to
that observed for the lysosome-speciﬁc membrane
damage inducer L-leucyl-L-leucine methyl ester (LLOMe;
Fig. 3a, b). The alkalinization of the lysosomal lumen leads
to pH-driven instability, which ultimately results in lyso-
somal membrane permeabilization (LMP)33,35. Galectin-1
(gal-1) localization changed from a diffuse to a punctate
pattern in the cytoplasm, conﬁrming LMP after LLOMe-
induced lysosomal pH alkalinization (Fig. 3c). A similar
gal-1 punctate staining pattern was observed in cells
treated with VP for both HCC cell lines in a dose-
dependent manner, with this more pronounced in HuH7
than HepG2 cells (Fig. 3c). As a marker for lysosomal
instability, the expression of lysosomal-associated mem-
brane protein 1 (LAMP-1) was assessed and was found to
be hyperglycosylated (H-Glyc) in HuH7 cells treated with
LLOMe and VP (Fig. 3d). While, in HepG2 cells, VP
induced a dose-dependent increase of LAMP-1 (Fig. 3d).
VP- and LLOMe-induced toxicity of lysosomes was also
accompanied by increased levels of cleaved PARP, parti-
cularly in HuH7 (Fig. 3d). This observation supports the
greater cytotoxicity observed in HuH7 cells compared to
HepG2 cells (Fig. 1a, b), suggesting a caspase-independent
necrotic process after VP treatment (Supplementary Fig.
S1E). These results indicate that VP is a lysosomotropic
compound and induces lysosomal membranes permea-
bilization after the alkalinization of intraluminal pH in
HCC cell lines.
VP-induced LMP provokes the dysregulation of
intracellular catabolic mechanisms, ﬁnally leading to a
proteotoxic effect
Having observed an induction of LMP by VP, we
investigated if its cytotoxic effect was enhanced by serum
deprivation, where tumor cells rely more on intracellular
catabolism36. Under serum deprived conditions, there was
a greater loss of cell viability in a VP dose-dependent
manner compared to normal culture conditions in both
HCC cell lines (Fig. 4a). Under reduced serum culture
conditions, VP treatment induced a dose-dependent
(see ﬁgure on previous page)
Fig. 1 VP potentiates the anti-tumor effect of SF in vitro and in vivo. a Mean ± SD of HuH7 and HepG2 relative viability was analyzed after 24 h
of VP treatment at different concentrations. Values were normalized to untreated cells, n= 3. b Mean ± SD relative of HuH7 and HepG2 LDH release
after 24 h treatment with verteporﬁn (VP – 20 μM). Values were normalized to untreated cells. n= 3. c Mean ± SD of HuH7 and HepG2 relative
viability was analyzed after 24 h treatment with sorafenib (SF – 5 μM) or in combination with verteporﬁn (SF – 5 μM/VP - 20 μM). Values were
normalized to untreated cells. n= 3. d Mean ± SD relative of HuH7 and HepG2 LDH release after 24 h treatment with sorafenib (SF - 5 μM) or in
combination with verteporﬁn (SF – 5 μM/VP – 20 μM). Values were normalized to untreated cells. n= 3. e Representative bright-ﬁeld images of HCC
patient–derived tumoroids treated with SF (5 μM), VP (20 μM), both drugs combined together (SF/VP) and vehicle-treated for 2 days. Scale bar 50 μm.
f Mean ± SD of ATP level detected by CellTiter-Glo® 3D Cell Viability Assay (Promega) of HCC patient-derived tumoroids (PDT) after SF (5 μM), VP
(20 μM) and both drugs combined together (SF/VP) treatment for 2 days. Values were normalized to vehicle-treated PDT after 2 days, n= 3. g Tumor
volume of HCC patient-derived xenografts mice (n= 3/group) treated with vehicle, verteporﬁn (VP – 100 g/kg – i.p. every second day), sorafenib (SF –
60 g/kg – daily oral gavage) and VP/SF combination for 14 days. h HCC PDX immunohistochemistry for Ki67 and CD31 (black arrows) in vehicle, VP, SF
and VP/SF treated animals after 14 days. Counterstain: hematoxylin. Scale bar 200 μm. The graphs show the mean percentage ± SD of Ki67 positive
cells and CD31 positive areas per tumor/mouse (three random ﬁelds were used for the analysis per tumor/mouse). i HCC PDX real-time qPCR data of
cell-cycle progression (CCNA2 and CCNB1) and vascular endothelial growth factor A (VEGF-A) genes after VP, SF and VP/SF treated animals after
14 days. Values were normalized to the vehicle-treated mice. P values < 0.05 were considered statistically signiﬁcant and are indicated as follows:
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not signiﬁcant
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Fig. 2 VP targets the lysosomal compartment. a Representative live HuH7 and b HepG2 cell-images showing the co-localization of the VP
autoﬂuorescence after 24 h in the Cy5 channel and Lysotracker staining (1 h, 100 nM) in the Cy3 channel. Nuclei were stained with DAPI. Scale bar 25 μm
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Fig. 3 VP-induced lysosomal pH alkalinization induces LMP. a Illustrative histograms from ﬂow cytometry showing the shifted FITC-dextran
emission wavelength after different concentrations of VP (24 h), LLOMe (6 h, 2.5 mM) and DMSO treatment on HuH7 and b HepG2. The graphs show
the results from lysosomal pH measurement on HuH7 and HepG2, n= 3. c Representative LMP galectin-1 staining (white arrows) in HuH7 and HepG2
upon VP (24 h) and the positive control LLOMe (6 h, 2.5 mM) treatment. Nuclei were stained with DAPI. Scale bar 50 μm. d Immunoblots for PARP,
LAMP-1 and β-actin in HuH7 and HepG2 cells after VP (24 h) and LLOMe (6 h, 2.5 mM) treatment. P values < 0.05 were considered statistically
signiﬁcant and are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not signiﬁcant
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Fig. 4 (See legend on next page.)
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decrease in expression of heat shock protein (Hsp70), an
evolutionarily conserved molecular chaperone that inhi-
bits LMP (Fig. 4b and Supplementary Fig. S3B), thereby
conﬁrming a broad lysosomal compartment instability37.
Moreover, VP-induced LMP led to a decreased expression
of LC3-I on HuH7 compared to HepG2, where instead an
accumulation of mature autophagosomes (LC3-II) was
mainly detected (Fig. 4b and Supplementary Fig. S3B). To
investigate the effect of VP on the autophagic ﬂux, we
used two late-stage autophagy inhibitors, chloroquine
(CQ) and baﬁlomycin A1 (BafA). We found that the
combination of CQ and BafA with VP under serum
deprived conditions resulted in a decreased level of LC3-II
accumulation in both cell lines compared to CQ and BafA
alone, suggesting that VP reduces autophagic ﬂux
(Fig. 4c). On the basis of the known localization of WIPI-1
on the membrane of phagophores38, we found a decreased
expression of GFP-WIPI-1 cytoplasmic puncta in both
cell lines (Supplementary Fig. S3C), conﬁrming that VP
reduces autophagy. Interestingly, we conﬁrmed the VP-
induced impairment of high–molecular weight oligo-
merized proteins bound to the sequestrome/cargo protein
p62 (HMW-p62) clearance39, which signiﬁcantly accu-
mulate after VP treatment (Fig. 4d), leading to proteo-
toxicity, autophagic ﬂux interference and LMP. These
results suggest that VP-induced LMP seems to be tumor-
speciﬁc. In malignant cells these phenomena provoke an
important catabolic dysregulation, which ﬁnally leads to
an unsolvable intracellular proteotoxicity.
The tumor-speciﬁcity of VP-induced lysosomal
compartment dysregulation, autophagic ﬂux blockade and
proteotoxicity
We conﬁrmed the high tropism of VP for the lysosomal
compartment also on primary human hepatocytes
(Fig. 5a). An increased number of VP-loaded lysosomes
was observed only for the highest dose of VP-treated
hepatocytes after 24 h (Fig. 5a). An increase in the pH of
the lysosomes towards alkaline values was not observed
(Fig. 5b). The VP-induced cytotoxic effect previously
observed was speciﬁc to HCC cells as there was no LDH
released from primary isolated human hepatocytes treated
with VP (Fig. 5c). No proteotoxic effect on primary iso-
lated human hepatocytes was observed after VP treat-
ment, with no changes in LAMP-1 glycosylation, LC3B
expression compared to the control (Fig. 5d). The
autophagic ﬂux progression in the presence of CQ and
BafA was not modulated in the presence of VP (Fig. 5e), as
was observed for HCC cell lines (Fig. 4c). An increase of
p62 was observed with VP alone and in combination with
the two autophagy inhibitors without any HMW-p62
accumulation (Fig. 5e). These results conﬁrm VP as a
lysosomotropic compound, able to induce a tumor-
speciﬁc LMP after the alkalinization of intraluminal pH.
Sorafenib treatment leads to an accumulation of
lysosomes in vitro and in vivo
According to the Drug Bank database that SF has
similar chemical properties to the other TKIs (acid dis-
sociation constant - pKa and lipophilicity coefﬁcient -
logP)5, we therefore tested the afﬁnity of SF for the lyso-
somal compartment. We found a cytoplasmic increase of
LysoTracker-stained lysosomes in HuH7 and HepG2 cells
after SF treatment (Fig. 6a and Supplementary Fig. S4A).
The acidic intraluminal pH was not altered with SF, while
VP alone or in combination with SF resulted in a sig-
niﬁcant alkalinization of lysosomal pH (Fig. 6b). SF alone
did not alter the expression of LAMP-1 or Hsp70 com-
pared to the control-treated cells (Fig. 6c). A lower gly-
cosylation of LAMP-1 and a lower expression of Hsp70
were observed for both HCC cell lines treated with SF/VP,
suggesting that SF seems to be passively sequestered into
lysosomes, which then are permeabilized by VP (Fig. 6c).
A slight increased lipidation rate of the autophagic protein
LC3B was detected in both HCC cell lines after SF
treatment, conﬁrming the known induction of autophagy
compared to the controls (Fig. 6c and Supplementary Fig.
S4B)19. After SF/VP treatment, the progression of
autophagy was almost completely blocked in both HCC
cell lines (Fig. 6c and Supplementary Fig. S4B). Looking at
autophagic ﬂux modulation, we found that the combina-
tion of CQ and BafA with SF resulted in a signiﬁcant
(see ﬁgure on previous page)
Fig. 4 VP-induced dysregulation of the intracellular catabolic machinery provokes a broad tumor-speciﬁc proteotoxic effect. a Mean ± SD
relative viability of HuH7 and HepG2 cells was analyzed after 24 h with various concentrations of verteporﬁn (VP) treatment under normal (complete
medium supplemented with 10% of fetal-bovine serum- FBS) and starving culture conditions (complete medium+ 0.1%FBS) and values were
normalized to vehicle-treated cells, n= 3. b Immunoblots for Hsp70, LC3B and β-actin in HuH7 and HepG2 cells after different concentrations of VP
(24 h) under normal (complete medium+ 10% FBS) and starving culture conditions (complete medium+ 0.1%FBS). c HuH7 and HepG2 cells were
treated with VP (20 μM, 24 h) ±chloroquine (CQ - 20 μM, 4 h) or Baﬁlomycin A1 (BafA - 100 nM, 4 h) under starving culture conditions (complete
medium+ 0.1%FBS) before western blot analysis for p62 and LC3B was performed. β-actin served as a loading control. LC3B carrier ﬂux data were
generated by normalizing the LC3B-II levels to β-actin followed by substraction of the BafA/CQ untreated sample from its respective BafA/CQ
stimulated condition. Flux under control condition was set to 1. d Representative immunoblots for p62 and β-actin in HuH7 and HepG2 cells after VP
(16 and 24 h) treatment. P values < 0.05 were considered statistically signiﬁcant and are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P <
0.0001; ns, not signiﬁcant
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induction of autophagy (Supplementary Fig. 4C-D). The
SF-induced autophagic ﬂux was signiﬁcantly impaired in
combination with VP in both HCC cell lines (Supple-
mentary Fig. 4C-D). No relevant regulation of p62
expression was observed for SF alone or in combination
with the two autophagy inhibitors, while proteotoxicity
was detected only in the presence of VP (Fig. 6c and
Supplementary Fig 4C). We also analyzed the expression
of the transcription factor EB (TFEB) target genes in the
coordinated lysosomal expression and regulation
(CLEAR) network40 (Supplementary Fig. 4E). TFEB was
signiﬁcantly upregulated in SF-treated HCC cell lines, but
were downregulated with VP and much more in SF/VP-
treated cells (Supplementary Fig. 4E). LAMP-1 expression
was upregulated in SF-treated cells, while signiﬁcantly
downregulated in the presence of VP for the most sensi-
tive cell line HuH7 (Supplementary Fig. 4E). Interestingly,
by looking at the expression of genes involved in lysoso-
mal hydrolase (cathepsin D – CTSD) and lysosomal
acidiﬁcation (ATPase H+ transporting V0 subunit D2 –
ATP6V0D2; Chloride channel 7 – CLCN7) we found a
SF-induced upregulation (especially in HuH7 cells). In
contrast, they were signiﬁcantly downregulated with VP
as a single treatment and even more in combination with
SF (Supplementary Fig. 4E). Similar results were also
obtained for PDTs, where SF/VP treatment led to a higher
glycosylation status of LAMP-1, an impairment of
autophagy progression (higher LC3-II accumulation) and
an increased proteotoxic effect (HMW-p62; Fig. 6d).
Similar to the in vitro models, an accumulation of LAMP-
1-stained lysosomes was observed in PDXs with SF
treatment compared to vehicle-treated mice (Fig. 6e). VP-
autoﬂuorescence was also detectable in the lysosomal
compartment within the PDX tumor cryosections, where
indeed the SF/VP-treated animals showed a decrease of
intra-tumoral accumulation of LAMP-1 (Fig. 6e). Given
its importance in cell growth and metabolism in HCC41,
we analyzed the target of rapamycin (TOR) and the status
of its downstream targets P70-S6 Kinase 1 (S6K) and the
eukaryotic translation initiation factor 4E (eIF4E)-binding
protein 1 (4E-BP1). We found a signiﬁcantly decreased
expression of mTOR and phospho-mTOR (p-mTOR)
proteins after VP treatment either alone or in combina-
tion with SF for both HCC cell lines (Supplementary Fig.
5A-B). Same signiﬁcant trend was observed for the
expression of the phosphorylated forms of S6 kinase and
4E-BP1 in the presence of VP, especially in HuH7 cells
compared to HepG2 (Supplementary Fig. 5A-B). VP-
induced lysosomal compartment instability and dysregu-
lation of the autophagic machinery observed in vitro were
conﬁrmed in the PDX model, with an increased glycosy-
lation rate of LAMP-1 and HMW-p62 proteotoxic
aggregates, accompanied by a consequent inverted
expression of LC3B (Supplementary Fig. S5C). We
showed that SF is lysosomotropic, leading us to hypo-
thesize that it could also be sequestered in the lumen of
lysosomes. Therefore VP-induced lysosomal pH alkalini-
zation, LMP and proteotoxicity are the main molecular
events of the interaction with SF.
RAS oncoprotein status seems to modulate the sensitivity
to VP-induced toxicity and lysosomal pH alkalinization in
HCC cell lines
The intracellular molecular targets of SF on epithelial
tumor cells are v-raf murine sarcoma viral oncogene
homolog B1 (B-RAF) and murine leukemia viral oncogene
homolog 1 (Raf1)42. We did not observe a decrease of ERK
phosphorylation (pERK) in both HCC cell lines after SF
treatment (Fig. 7a, b). We found that only after VP-
induced LMP there was a signiﬁcant decrease of total ERK
(tERK) and pERK protein expression either alone (HuH7)
or in combination with SF for both HCC cell lines
(Fig. 7a, b). Keeping in mind the marked and persistent
different responsiveness observed in HuH7 and HepG2
cells and the different expression of pERK after VP, SF
and SF/VP treatment, we attempted to investigate the
activity of the MAPK pathway signaling nodes located
upstream of ERK, by assessing the expression of the small
GTPase human Rat Sarcoma (RAS) oncoprotein. Indeed,
VP decreased the expression of RAS, which was even
more pronounced in combination with SF (Fig. 7a, b). Due
to the fact that cancer cells often have multiple genetic
(see ﬁgure on previous page)
Fig. 5 The cytotoxicity and proteotoxicity of VP is tumor-speciﬁc. a Isolated primary human hepatocytes live imaging showing the co-
localization of VP autoﬂuorescence after 24 h in the Cy5 channel and Lysotracker staining (1 h, 100 nM) in the Cy3 channel. Nuclei are marked
with “ *”. Scale bar 25 μm. b Illustrative histograms from ﬂow cytometry showing FITC-dextran emission wavelength after VP and DMSO 24 h
treatment on primary human hepatocytes. The graph shows the results from lysosomal pH measurement. n= 3. c Mean ± SD relative LDH release in
primary human hepatocytes exposed to increasing concentrations of VP and DMSO for 24 h. Values were normalized to untreated primary human
hepatocytes. n= 3. d Immunoblots for LAMP-1, p62, LC3B and β-actin in isolated primary human hepatocytes after different concentrations of VP
(24 h) treatment. e Primary human isolated hepatocytes were treated with VP (20 μM, 24 h) ±chloroquine (CQ - 20 μM, 4 h) or Baﬁlomycin A1 (BafA –
100 nM, 4 h) before western blot analysis for p62 and LC3B was performed. β-actin served as a loading control. LC3B carrier ﬂux data were generated
by normalizing the LC3B-II levels to β-actin followed by substraction of the BafA/CQ untreated sample from its respective BafA/CQ stimulated
condition. Flux under control condition was set to 1. P values < 0.05 were considered statistically signiﬁcant and are indicated as follows: *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not signiﬁcant
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Fig. 6 SF induces an accumulation of lysosomes in vitro and in vivo. a Representative HCC cell-images live-stained with Lysotracker (1 h, 100 nM)
in the Cy3 channel, treated with sorafenib (SF, 5 μM) for 24 h. Nuclei were stained with DAPI. Scale bar 25 μm. b Mean ± SD of lysosomal pH values
measured by ﬂow cytometry in HuH7 and HepG2 pre-incubated in culture medium supplemented with FITC-dextran (0.1 mg/mL, 72 h) after
treatment with SF (5 μM), VP (20 μM) and both drugs combined together (VP/SF) for 24 h. n= 3. c Representative immunoblots for LAMP-1, Hsp70,
p62, LC3B, and β-actin in HuH7 and HepG2 cells after VP (20 μM, 24 h), SF (5 μM, 24 h) treatment and both compounds combined together.
d Representative immunoblots for LAMP-1, p62, LC3, and β-actin in HCC patient-derived tumoroids (PDT) after VP (20 μM, 24 h), SF (5 μM, 24 h)
treatment and both compounds combined together, n ≥ 3. e Illustrative immunoﬂuorescence images on cryosections of LAMP-1 and VP
autoﬂuorescence (Cy5 channel) from HCC patient-derived xenografts after 14 days of treatment with vehicle, VP, SF and SF/VP. Nuclei were stained
with DAPI. Scale bar 50 μm. P values < 0.05 were considered statistically signiﬁcant and are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001; ns, not signiﬁcant
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aberrations leading to differences in drug sensitivity43,44
and having observed a signiﬁcant LMP-induced reduction
of RAS oncoprotein expression, we then tested the
efﬁcacy of VP on a panel of seven distinct HCC cell lines
differing in their RAS status (wild-type and mutated) and
mutant B-RAF (SK-Hep-1 cell line). The negative effect
Fig. 7 RAS status modulates cell sensitivity during lysosomal pH alkalinization induced by VP. a Representative immunoblots and
quantiﬁcation, b for pERK, tERK, pan RAS and β-actin in HuH7 and HepG2 cells after VP (20 μM, 24 h), SF (5 μM, 24 h) treatment and both compounds
combined together. c Mean of relative viability and d LDH release of a panel of eight different HCC cell lines was analyzed after 72 h of verteporﬁn
(VP – 20 μM) treatment and values were normalized to vehicle-treated (DMSO) cells. Both box plot graphs show the mean values from the eight HCC
cell lines grouped by their speciﬁc RAS and RAF status. P values < 0.05 were considered statistically signiﬁcant and are indicated as follows: *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not signiﬁcant
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on cell viability as well as the cytotoxic LDH release
induced by VP was stronger on wild-type RAS HCC cell
lines than the mutant RAS and B-RAF cell lines (Fig. 7c, d
and Supplementary Fig. S5A-B). These results show that
SF-induced lysosomes accumulation correlates with a
decreased availability and efﬁcacy at its intracellular target
site. It might suggest an important role of the RAS-status
in the context of lysosomal compartment stability after
LMP in HCC cell lines.
Discussion
In this study we have revealed an alternative mechanism
of action of VP in the context of cancer therapy, in which
it is sequestered in lysosomes and thereby alters lysosomal
function. VP, similarly to the well-described lysosome-
speciﬁc membrane damage inducer LLOMe, triggers an
alkalinization of lysosomal pH and a consequent induc-
tion of LMP45,46. The sequestering of VP in the lysosomal
compartment of HCC cells results in cell toxicity, which
was not observed in non-malignant liver cells. Hepatocyte
survival was not affected by VP, whereas malignant cells
underwent LMP, with an increased proteotoxicity mainly
caused by lysosomal pH alkalinization and consequent
non-functional intracellular catabolic mechanisms. Pre-
vious studies have shown differences in lysosomal
compartment stability between normal and malignant
cells under normoxic or hypoxic and nutrient-deprived or
nutrient-rich environments47. While normal tissue has a
lower grade of stress induced by proteosomal and
autophagic recycling processes, tumor cells show a
heightened susceptibility upon exposure to lysosomal-
mediated cell death agents24,47. There are numerous
cancer therapeutics that are ultimately sequestered to the
lysosome9,48,49. Anti-cancer therapy can be diminished or
can lead to drug resistance, as the concentration of lyso-
somotropic compounds is reduced and they are physically
unable to reach their molecular target sites10,50,51. Based
on the predictive mathematical model reported by Trapp
et al.52, we found that SF is also lysosomotropic. We
showed that SF, by inducing a signiﬁcant increase of
lysosomes in vivo and in vitro, could also be sequestered
in the lumen of lysosomes. The lysosomotropism of SF
did not alter all the lysosomal stability markers (intra-
luminal pH, LAMP-1, and Hsp70), compared to what we
observed in cells treated with VP. Here we propose to
combine SF with VP in order to elicit a dual inhibitory
effect on autophagy and lysosomal compartment. After
the passive lysosomal sequestration of SF and a signiﬁcant
upregulation of TFEB and LAMP-1 genes, VP induces an
alkalinization of intraluminal lysosomal pH and LMP with
Fig. 8 Proposed model of synergic interaction of sorafenib and verteporﬁn. Sorafenib treatment induces an accumulation of lysosomes and is
passively sequestered within their acid lumen. These phenomena reduce SF intracellular concentration and distribution at the target site. The
lysosomotropic compound VP, either alone or in combination with SF, accumulates in lysosomes, actively induces an alkalinization of intraluminal pH
which then leads to a diffuse lysosomal membrane permeabilization. VP-induced lysosomal compartment instability leads to a broad autophagic ﬂux
dysregulation and consequent proteotoxic effect
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a signiﬁcant downregulation of CLEAR genes involved in
lysosomal hydrolase and acidiﬁcation. In our in vitro and
in vivo models, we conﬁrmed that SF enhanced autophagy
compared to the controls19, while conversely it was
blocked in combination with VP. A greater accumulation
of lysosomes was also observed in PDXs after SF treat-
ment, which was ultimately abrogated by VP, accom-
panied by an increase of the glycosylation rate of LAMP-1.
When HuH7 or HepG2 (both B-RAF wild type) were
treated with SF, we did not observe a decrease in the
phosphorylation of the downstream ERK1/2 kinase, which
may be due to its accumulation in the acidic lumen of
lysosomes and a drastically decreased concentration at its
target site. An overwhelmed lysosomal compartment
stability has been described as an uncontrolled process,
where the release of acidic content and proteases into the
cytoplasm after LMP can lead to necrosis without any
caspase activation53. Similarly to previous observations54,
we showed that the VP-induced cleavage of PARP in
in vitro and in vivo models, suggests a caspase-
independent necrotic process due to the release of the
acidic content and proteases from the permeabilized
lysosomal lumens. We conﬁrmed that after SF treatment,
the viability of HCC cell lines and patient-derived
tumoroids was not reduced34. Interestingly, we found
that in tumor cells treated with VP there was a marked
decrease in RAS protein expression, an effect that was
even more pronounced in combination with SF. Knowing
the peripatetic role of RAS and its physical co-localization
with LAMP-155,56, we demonstrated that VP-induced
LMP correlates with the proportional proteolysis of RAS
in tumor cells. We were also able to show a RAS-
dependent sensitivity to LMP, where cells with mutated
RAS were less sensitive to VP-induced LMP then the RAS
wild-type HCC cell lines. Taken together, our data suggest
that the hydrophobic and weak-base tyrosine kinase
inhibitor SF seems to be passively sequestered in lyso-
somes, which then leads to a reduction of its cytoplasmic
concentration and therefore access to its target sites. This
can result in a loss of tumor cell SF-induced toxicity and
induce drug resistance (Fig.8). Instead, VP is also
sequestered in the lysosomal lumen, but then it actively
induces a high lysosomal compartment destabilization
and an autophagy dysregulation. These phenomena are
caused by a VP-induced alkalinization of the lysosomal
pH, followed by a tumor-speciﬁc cytotoxic accumulation
of misfolded proteins, which ultimately potentiate the
anti-tumor effect of SF (Fig. 8). The VP-induced tumor-
selective proteotoxic effect and LMP, may prove critical in
treating tumors, whose therapeutic options are limited.
Used in combination with SF, VP might help to overcome
chemo-insensitivity caused by passive lysosomal seques-
tration of anti-cancer drugs and ameliorate HCC-patient
outcomes.
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